KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Preferred Dividend Payments (2018 - 2022)

Xenon Pharmaceuticals (XENE) has disclosed Preferred Dividend Payments for 6 consecutive years, with $805000.0 as the latest value for Q3 2022.

  • On a quarterly basis, Preferred Dividend Payments rose 122.38% to $805000.0 in Q3 2022 year-over-year; TTM through Sep 2022 was $909000.0, a 45.01% decrease, with the full-year FY2021 number at $1.8 million, up 117.84% from a year prior.
  • Preferred Dividend Payments was $805000.0 for Q3 2022 at Xenon Pharmaceuticals, up from -$684000.0 in the prior quarter.
  • In the past five years, Preferred Dividend Payments ranged from a high of $1.6 million in Q3 2018 to a low of -$684000.0 in Q2 2022.
  • A 5-year average of $420222.2 and a median of $371000.0 in 2019 define the central range for Preferred Dividend Payments.
  • Peak YoY movement for Preferred Dividend Payments: surged 10320.0% in 2021, then plummeted 231.29% in 2022.
  • Xenon Pharmaceuticals' Preferred Dividend Payments stood at $1.6 million in 2018, then plummeted by 73.97% to $422000.0 in 2019, then fell by 17.77% to $347000.0 in 2020, then soared by 40.92% to $489000.0 in 2021, then soared by 64.62% to $805000.0 in 2022.
  • Per Business Quant, the three most recent readings for XENE's Preferred Dividend Payments are $805000.0 (Q3 2022), -$684000.0 (Q2 2022), and $299000.0 (Q1 2022).